Journal of Preventive Cardiology
spacer
Current Issue

State-of-the-art-article

Year: 2016 I  Volume: 6I  Issue: 1I  Pages:947–953
 

Familial hypercholesterolemia - An underdiagnosed and undertreated entity

Dr. J P S Sawhney*, DM; Sourabh Bagga†, DM; Simran Sawhney‡, MBBS

*Chairman, Department of Cardiology, Dharma Vira Heart Centre, Sir Ganga Ram hospital, New Delhi-110060, India

†Senior Resident, Department of Cardiology, G B Pant Hospital, New Delhi

‡ Post Graduate Medicine, St. Stephen Hospital, Delhi -110054

 

Abstract

Familial hypercholesterolemia (FH) is a common autosomal-dominant disorder characterized by a raised level of low-density lipoprotein cholesterol (LDL-C) and a high risk of premature coronary heart disease (CHD). Diagnosis of FH largely relies on the evaluation of LDL-C levels, a careful documentation of family history, and the identification of clinical features. FH is underdiagnosed and undertreated, with only 1% being treated even in developed nations.

The primary goal for the treatment of FH is to reduce mortality and atherosclerotic cardiovascular disease events, which is achieved by reducing plasma LDL levels. European Society of Cardiology (ESC) guidelines recommend LDL goal of 70-100 mg/dL depending on associated cardiovascular disease risk. Statins are presently the mainstay in the management of these patients. A substantial population of patients cannot take advantage of statin therapy as they do not reach LDL goal despite using maximum tolerated doses or due to statin intolerance, suggesting a need for additional effective agents to reduce LDL-C levels. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors such as evolocumab and alirocumab are newer treatment options which provide additional options to further lower LDL levels. Evolocumab and alirocumab are fully human monoclonal immunoglobulin G2 (IgG2) directed against human PCSK9. By inactivating PCSK9, they upregulate LDL receptors, thereby increasing catabolism of LDL-C and consequently reducing LDL-C levels in blood.

In this article, we review FH, complexity of diagnosis and management, and newer treatment options like PCSK9 inhibitors that could help improve the management of FH.

 
Keywords
Familial hypercholesterolmia
LDL-cholesterol
Statin Therapy
Evolocumab
 
[Full Text]
Print this Article
Back to main page
Slideshow
  • State-of-the-art Article
    Epidemiology of Diabetes Mellitus in India
    -Dr. Benudhar Nath*, MBBS, MD; Dr. Manash P Baruah
    abstract text full text
  • Review Article
    Diabetic Dy slipidemia-a review
    -Prof. (Col) Surender Kumar, Narendra Kotwal,
    abstract text full text
  • Updates on Statins
    full text
  • News and Views
     
    full text
  • Forthcoming Events
     
    full text
spacer
Slideshow
  • 72nd Annual Conference (2017) of The Association of Physicians of India
    To be held on January 26-29 2017, Mumbai, India
    Read more...
  • Belgian Society of Cardiology 36th Annual Scientific Meeting 2017 (BSC 2017)
    To be held on February 09-10 2017, Brussels
    Read more...
  • Indian Society of Electro cardiology Conference 2017 (ISECON 2017)
    To be held on February 11-12 2017, New Delhi, India
    Read more...
  • 7th World Congress of Diabetes India 2017
    To be held on February 23-26 2017, New Delhi, India
    Read more...
Journal of Preventive Cardiology
spacer
 
spacer
Print ISSN: 2249-4308
Online ISSN: 2277-6559
 
Frequency: Quarterly
 
 
Email This
close
 
 
  [ Separate multiple email addresses with commas (Limit is 10). ]